Related Articles
Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation
NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells
shRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib